Biosimulation company Certara said on Thursday that the international registry of healthcare workers will collect information on risk factors for developing COVID-19 as well as using preventative therapies in protecting the healthcare workers during today's global health crisis and for future outbreaks, under The International Registry of Healthcare Workers Exposed to COVID-19 (UNITY Global).
Under UNITY Global, Certara will enable prevention policies based on real-world data collected from 10,000 healthcare workers in low- and middle- income countries. The initiative was funded by the COVID-19 Therapeutics Accelerator. The primary objective is to assess the association between the use of preventive treatments and the occurrence of SARS-CoV-2 infection in healthcare workers.
The company stated the registry first launched in Pakistan on 3 August 2020 and will enroll 10,000 healthcare workers. Additional countries preparing for launch of the registry include South Africa, Nigeria, Kenya, Uganda, Senegal, Zambia and Zimbabwe. The registry collects information on a weekly basis from enrollees across a 12-week period. The registry will record SARS-CoV-2 antibody test results.
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Everest Medicines expands I-MAB investment
Perrigo Announces Quarterly Dividend
Ridgetech reports net income of USD10.20m in fiscal year 2025